Role of insulin in management of type 2 diabetes mellitus

Sujay S. Patil; Manthan Mehta; Vaishali Thakare; Shrikrishna Shende; Prashant A. Shirure; Onkar C. Swami

doi:10.18203/2320-6012.ijrms20172422

Authors

Sujay S. Patil Department of Pharmacology, D Y Patil University School of Medicine, Navi Mumbai, Maharashtra, India
Manthan Mehta Department of Pharmacology, T.N.M.C. and Nair Hospital, Mumbai, Maharashtra India
Vaishali Thakare Department of Pharmacology, D Y Patil University School of Medicine, Navi Mumbai, Maharashtra, India
Shrikrishna Shende Department of Pharmacology, D Y Patil Medical College, Pune, Maharashtra India
Prashant A. Shirure Department of Pharmacology, Dr. V. M. Medical College, Solapur, Maharashtra India
Onkar C. Swami Head, Medical Services, Unichem Laboratories Ltd, Mumbai, Maharashtra India

DOI:

https://doi.org/10.18203/2320-6012.ijrms20172422

Keywords:

Diabetes mellitus, Insulin therapy, Recombinant insulin, Replacement insulin

Abstract

The prevalence of type 2 diabetes mellitus and its resultant morbidity and mortality is rapidly increasing. An important factor in reducing the microvascular complications of diabetes is strict glycemic control. Most patients require additional insulin therapy in spite of regularly taking oral anti-diabetic drugs. Though classically used later in the natural course of the disease, newer treatment guidelines suggest early initiation of insulin analogues. The discovery of insulin has been hailed as one of the most dramatic events in the history of diabetes, improving the life-span of most diabetics. Replacement insulin therapy should mimic physiological insulin release patterns. Modern insulin and its analogues have been developed to serve as an ideal replacement therapy. There are various insulin preparations available in the market and each of them has their own advantages and disadvantages. The modern insulin’s have been developed to overcome certain side effects of the older preparations. A range of insulin products are under development that aim to increase absorption prolong action and provide alternative delivery methods. Greater patient adherence is important since most patients are reticent about insulin therapy. This review describes the role of insulin in the management of type 2 diabetes mellitus.

Metrics

Metrics Loading ...

References

Echelbarger N, Lanham H, Close K. Diabetes Close Up: DCU Book Review #1. Michael Bliss: The Discovery of Insulin. Available at http://www.closeconcerns.com/dcu/DCU%20 BR%20V-1.pdf.

Anderson T, Breecher MM. Science Heroes. Frederick Banting, MD. Available at http://scienceheroes.com/index.php?option=com_content&view=article&id=80&Itemid=115.

Ritzel RA, Bulter PC. Physiology of glucose homeostasis and insulin secretion. Insulin Therapy. New York, NY: Marcel Dekker. 2002:61-72.

Prospective UK. UK prospective diabetes study 16. Overview of 6 years’ therapy of type II diabetes: a progressive disease. Diabetes. 1995;44(11):1249-58.

Turner RC, Cull CA, Frighi V, Holman RR. UK Prospective Diabetes Study (UKPDS) Group. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS49). JAMA. 1999;281(21):2005-12.

Brunton S.“Beyond glycemic control: treating the entire type 2 diabetes disorder,” Postgraduate Medicine. 2009;121(5):68-81.

Cobble ME, Peters AL. “Clinical practice in type 2 diabetes: after metformin and lifestyle, then what?”. J FamPracti.2009;58(11):S7-S14.

Vasiliki V. Therapeutics of Diabetes Mellitus: Focus on Insulin Analogues and Insulin Pumps. Exp Diabetes Res. 2010;2010.

The history of Insulin. Basel, Switzerland; S.KargerAG. Available at http://content.karger.com / ProdukteDB / Katalogtelie/sbn3_8085/_83/_53/Insulin_02.pdf.Published 2012.

Rodbard HW, Jellinger PS, Davidson JA, Einhorn D, Garber AJ, Grunberger G et al. Statement by an American association of clinical endocrinologists/American college of endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract. 2009;15(6):540-59.

Griffin SJ, Borch-Johnsen K, Davies MJ, Khunti K, Rutten GE, Sandbæk A et al. Effect of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with type 2 diabetes detected by screening (ADDITION-Europe): a cluster-randomized trial. Lancet.2011; 378(9786):156-67.

Weyer C, Bogardus C, Mott DM, Pratley RE. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest.1999;104(6):787-94.

Wright A, Burden AC, Paisey RB, Cull CA, Holman RR. U.K. Prospective Diabetes Study Group. Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57). Diabetes Care. 2002;25(2):330-6.

Home P, Naggar NE, Khamseh M, Galvez GG, Shen C, Chakkarwar P et al. An observational non-interventional study of people with diabetes beginning or changed to insulin analogue therapy in non-Western countries: theA1chieve study. Diabetes Res Clin Pract 2011;94(3):352-63.

Litwak L, Goh SY, Hussein Z, Malek R, Prusty V, Khamseh ME. Prevalence of diabetes complications in people with type 2 diabetes mellitus and its association with baseline characteristics in the multinational A1chieve study. Diabetol Metab Syndr.2013;5(1):57.

Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577-89.

Gerstein HC, Bosch J, Dagenais GR, Díaz R, Jung H, Maggioni AP et al. ORIGIN Trial Investigators. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 2012;367(4):319-28.

Gerstein HC, Miller ME, Byington RP, Goff DC, Bigger JT, Buse JB et al. Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545-59.

Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009;360(2):129-39.

Michael Heile, Doron Schneider. The Evolution of Insulin Therapy in Diabetes Mellitus. J Fam Pract. 2012;61(5 Suppl):S6-12.

Rosenfeld L. Insulin Discovery and Controversy. Clin Chem. 2002;48(12):2270-88.

Humulin R. US Food and Drug Administration. Available from: http:// www.accessdata.fda.gov / scripts / cder/ drugs / index.cfm? fuseaction=Search Overview and Drug Name = HUMULIN20%R.

Mannucci E, Monami M, Marchionni N. Short-acting insulin analogues vs. regular human insulin in type 2 diabetes: a met analysis. Diabetes Obes Metab. 2009;11(1):53-9.

Rossetti P, Porcellati F, Fanelli CG, Perriello G, Torlone E, Bolli GB. Superiority of insulin analogues versus human insulin in the treatment of diabetes mellitus. Arch Physiol Biochem. 2008; 114(1):3-10.

Hilan-Dandan R, Laurence L. Brunton. Goodman and Gilman’s Manual of Pharmacology and Therapeutics 2nd Edition.

Diagnosis and management of Type 1 diabetes in children, young people and adults; NICE Clinical Guideline.2004.

Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368(9548):1696-1705.

Das AK. Ashida TS. Modern Insulins-The Insulin Analogues: A Reappraisal.Chapter 39.

M. Evans, P. M. Schumm-Draeger, J. Vora, A.B. King; A review of modern insulin analogue pharmacokinetic and pharmacodynamic profiles in type 2 diabetes: improvements and limitations; Diabetes, Obesity and Metabolism, Vol 13, No.8, 677-684 August 2011.

Howey DC, Bowsher RR, Brunelle RL, Woodworth JR. [Lys (B28), Pro(B29)]-human insulin: A rapidly absorbed analogue of human insulin. Diabetes 1994;43(3):396-402.

Eckardt K, Eckel J. Insulin analogues: action profiles beyond glycaemic control. Archives Physiol Biochem. 2008;114(1):45-153.

Giugliano D, Ceriello A, Razzoli E, Esposito. K. Defining the role of insulin lispro in the management of postprandial hyperglycaemia in patients with type 2 diabetes mellitus. Clin Drug Investig. 2008;28(4):199-210.

Home PD, Lindholm A, Hylleberg B, Round P. Improved glycemic control with insulin aspart: a multicenter randomized double-blind crossover trial in type 1 diabetic patients. Diabetes Care. 1998; 21(11):1904-9.

Chapman TM, Noble S, Goa KL. Spotlight on insulin aspart in type 1 and 2 diabetes mellitus. Treat Endocrinol. 2003;2(1):71-6.

Becker RH. Insulin glulisine complementing basal insulins: a review of structure and activity. Diabetes Technol Ther. 2007;9(1):109-21.

Garnock-Jones KP, Plosker GL. Insulin glulisine: a review of its use in the management of diabetes mellitus. Drugs. 2009;69(8):1035-57.

Heise T, Bott S, Rave K, Dressler A, Rosskamp R, Heinemann L. No evidence for accumulation of insulin glargine (Lantus): a multiple injection study in patients with Type 1 diabetes. Diabet Med 2002;19(6):490-5.

Hagenmeyer EG, Sch¨adlich PK, K¨oster AD, Dippel FW, Aussler BH. Quality of life and treatment satisfaction in patients being treated with long-acting insulin analogues. Dtsch Med Wochenschr. 2009;134(12):565-70.

Elrishi MA, Jarvis J, Khunti K, Davie MJ. Insulin glargine and its role in glycaemic management of Type 2 diabetes. Expert Opin Drug Metab Toxicol. 2008;4(8):1099-110.

Dea MK, Hamilton-Wessler M, Ader M. Albumin binding of acylated insulin does not deter action to stimulate glucose intake. Diabetes. 2002;51(3):762-9.

Morales J. Defining the role of insulin detemir in basal insulin therapy. Drugs. 2007;67(17):2557-84.

Jonassen I, Havelund S, Hoeg-Jensen T, Steensgaard DB, Wahlund PO, Ribel U. Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin. Pharm Res 2012;29(8):2104-14.

Nishimura E, Sorensen AR, Hansen BF, Stidsen C, Olsen GS. Insulin degludec, a new generation ultra-long acting basal insulin designed to maintain full metabolic effect while minimizing mitogenic potential. Diabetologia. 2010;53 (suppl 1):S388-89.

Heise T, Nosek L, Bottcher SG, Hastrup H, Haahr H. Ultra-long-acting insulin degludec has a flat and stable glucose lowering effect in type 2 diabetes. Diabetes Obes Metab. 2012;14(10):944-50.

Evans M, Wolden M, Gundgaard J, Chubb B, Christensen T. Cost-effectiveness of insulin degludec compared with insulin glargine for patients with type 2 diabetes treated with basal insulin-from the UK health care cost perspective. Diabetes Obes Metab. 2014;16(4):366-75.

European Medicines Agency. Toujeo (previously Optisulin). Available at http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000309/human_med_000955.jsp&mid=WC0b01ac058001d124 .

Bergenstal RM, Rosenstock J, Arakaki RF, Prince MJ, Qu Y, Sinha VP et al. A randomized, controlled study of once-daily LY2605541, a novel long-acting basal insulin, versus insulin glargine in basal insulin-treated patients with type 2 diabetes. Diabetes Care 2012; 35(11):2140-47.

Yki-Järvinen H, Bergenstal R, Ziemen M, Wardecki M, Muehlen-Bartmer I, Boelle E et al. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2). Diabetes Care. 2014;37(12):3235-43.

Riddle MC, Bolli GB, Ziemen M, Muehlen-Bartmer I, Bizet F, Home PD. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using basal and mealtime insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 1). Diabetes Care. 2014;37(10):2755-62.

Hartree N, Tidy C, Bonsal A l; Insulin Regimens, Available from: patient.info/doctor/insulin-regimens.

Diabetes - insulin pump therapy: Continuous subcutaneous insulin infusion for the treatment of diabetes (review); NICE Technology Appraisal Guidance. 2008.

Merendino J. What are advantages and disadvantages of insulin. Available from: www.share.com.

Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577-89.

Nathan DM, Cleary PA, Backlund J, Genuth SM, Lachin JM, Orchard TJ et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353(25):2643-53.

Nathan DM, Lachin J, Cleary P, Orchard, T, Brillon DJ, Backlund JY, et al. Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus. N Engl J Med. 2003;348(23):2294-2303.

Insulin therapy. Advantages and disadvantages of insulin pumps. Available from: www.prokerala.com.

Nice technology Appraisal: Inhaled Insulin -Diabetes UK response.1-10.

Fish HR, Chernow B, O'Brian JT. Endocrine and neurophysiologic responses of the pituitary to insulin-induced hypoglycaemia: a review. Metabolism.1986;35(8):763-80.

Sjolie AK. Ocular complications in insulin treated diabetes mellitus. Acta Ophthalmol Suppl. 1985;172:1-77.

Valenta LJ, Elias AN. Insulin-induced lipodystrophy in diabetic patients resolved by treatment with human insulin. Ann Intern Med.1985;102(6):790-1.

Johnson AOC, Mylvaganam K, Child DF. Generalised allergic reaction with synthetic human insulin. 1982 Dec 4;2(8310):1287.

Koh H, Nambu S, Tsushima M, Nishioheda Y, Murakami K, Ikeda M. l. The effects of insulin on the cardiovascular system in patients with coronary heart disease. Arzneimittelforschung. 1984;34(2):185-90.

Carlson MG, Campbell PJ. Intensive insulin therapy and weight gain in IDDM. 1993;42(12):1700-7.

Riddle MC. Relief of gastrointestinal symptoms by correcting insulin excess. 1981;4(2):296-8.

Sorti C. New Developments in Insulin Therapy for Type 2 Diabetes. Am J Med. 2014;127(10 Suppl):S39-48.

Moghissi E, King AB. Individualizing insulin therapy in the management of type 2 diabetes. Am J Med. 2014;127(Suppl 1):S3-S10.

Meneghini LF. Early Insulin Treatment in Type 2 Diabetes. Diabetes Care. 2009;32(Suppl 2):S266-269.

Heise T, Pieber TR. Towards peakless, reproducible and long-acting insulins. An assessment of the basal analogues based on isoglycaemic clamp studies. Diabetes Obes Metab.2007;9(5):648-59.

Bolli GB, Owens DR. Insulin glargine. Lancet. 2000;356(9228):443-5.

Approaches to Glycemic Treatment. Diabetes Care 2016;39(Suppl. 1):S52-9.

Peterson GE. Intermediate and long-acting insulins: a review of NPH insulin, insulin glargine and insulin detemir. Curr Med Res Opin. 2006;22(12):2613-9.

Rosskamp RH, Park G. Long acting insulin analogs. Diabetes Care.1999;22(Suppl 2):B109-113.

Monami M, Marchionni N, Mannuci E. Long-acting insulin analogues versus NPH human insulin in type 2 diabetes: a meta-analysis. Diabetes Res Clin Pract. 2008;81(2):184-9.

Kang S, Brange J, Birch A. Vølund A, Owens DR. Subcutaneous insulin absorption explained by insulin’s physicochemical properties. Evidence from absorption studies of soluble human insulin and insulin analogues in humans. Diabetes Care.1991;14(11):942-8.

Heinemann L, Heise t, Jorgensen LN, Starke AA. Action profile of the rapid acting insulin analogue: human insulin B28Asp. Diabet Med. 1993;10(6):535-9.

Novak B, Meteko Z. New Trends in Insulin Therapy. Diabetologica Croatica. 2003;32(2):55-63.

Lindholm A, Jacobsen LV. Clinical pharmacokinetics and pharmacodynamics of insulin aspart. Clin Pharmacokinet. 2001;40(9):641-59.

Pollak M. The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nat Rev Cancer. 2012;12(3):159-69.

Belfiore A, Frasca F, Pandini G, Sciacca L, Vigneri R. Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease. Endocr Rev. 2009;30(6):586-623.

Sciacca L, Cassarino MF, Genua M, Pandini G, Le Moli R, Squatrito S, et al. Insulin analogues differently activate insulin receptors isoforms and post-receptor signalling. Diabetologia. 2010;53(8):1743-53.

Janghorbani M, Dehghani M, Marzijarani MS. Systematic review and meta-analysis of insulin therapy and risk of cancer. Horm Cancer. 2012;3(4)137-46.

Kurtzhals P, Schaffer L, Sorensen A, Kristensen C, Jonassen I, Schmid C, et al. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes. 2000;49(6):999-1005.

Colhoun HM. Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group. Diabetologia. 2009;52(9):1755-65.

Hemkens LG, Grouven U, Bender R, Gunster C, Gutschmidt S, Selke GW, et al. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia. 2009;52(9):1732-44.

Currie CJ, Poole CD, Gale EA. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia. 2009;52(9):1766-77.

Morden NE, Liu SK, Smith J, Mackenzie TA, Skinner J, Korc M. Further exploration of the relationship between insulin glargine and incident cancer: a retrospective cohort study of older Medicare patients. Diabetes Care. 2011;34(9):1965-71.

Ruiter R, Visser LE, Sukel MPVH, Coebergh JW, Haak HR, Duijvestijn PHG, et al. Risk of cancer in patients on insulin glargine and other insulin analogues in comparison with those on human insulin: results from a large population-based follow-up study. Diabetologia. 2012;55(1):51-62.

Potenza MA, Addabbo F, Montagnani M. Vascular actions of insulin with implications for endothelial dysfunction. Am J Physiol Endocrinol Metab. 2009;297(3):E568-77.

Gerstein HC, Miller ME, Byington RP, Goff DC, Bigger JT, Buse JB, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545-59.

Weng J, Li Y, Xu W, Shi L, Zhang Q, Zhu D, et al. Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial. Lancet. 2008;371(9626):1753-60.

Gerstein HC, Bosch J, Dagenais GR, Diaz R, Jung H, Maggioni AP, et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med. 2012;367(4):319-28.

American Diabetes Association. Standards of medical care in diabetes-2012. Diabetes Care. 2012;35(suppl 1):S11-63.

Tibaldi JM. Evolution of insulin: from human to analog. Am J Med. 2014;127(Suppl 1):S25-38.

Jonassen I, Havelund S, Hoeg-Jensen T, Steensgaard DB, Wahlund PO, Ribel U, et al. Design of the novel protraction mechanism of insulin degludec, an ultra-long acting basal insulin. Pharm Res. 2012;29(8):2014-114.

Steensgaard DB, Schluckebier G, Strauss HM, Norrman M, Thomsen JK, Friderichsen AV et al. Ligand-controlled assembly of hexamers, dihexamers, and linear multihexamer structures by the engineered acylated insulin degludec. Biochemistry. 2013;52(2):295-309.

Nishimura E, Sorensen AR, Hansen BF, et.al. Insulin degludec, a new generation ultra-long acting basal insulin designed to maintain full metabolic effect while minimizing mitogenic potential. Diabetologica.2010;53 (Suppl 1):S388-89.

Currue CJ, Johnson JA. The safety profile of exogenous insulin in people with type 2 diabetes: justification for concern. Diabetes Obes Metab. 2012;14(1):1-4.

Lasserson DS, Glasziou P, Perera R, Holman RR, Farmer AJ. Optimal insulin regimens in type 2 diabetes mellitus: systematic review and meta-analyses. Diabetologica. 2009;52(10):1990-2000.

Caahn A, Miccoli R, Dardano A, Prato DS. New forms of insulin and insulin therapies for the treatment of type 2 diabetes. Lancet Diabetes Endocrinol. 2015;3(8):638-52.

Caparrotta TM, Evans M. PEGylated insulin Lispro (LY2605541)- a new basal insulin analogue. Diabetes Obes Metab. 2014;16(5):388-95.

Rosenstock J, Bergenstal RM, Blevins TC, Morrow LA, Prince MJ, Qu Y, et al. Better glycemic control and weight loss with novel long-acting basal insulin LY2605541 compared with insulin glargine in type 1 diabetes: a randomized, crossover study. Diabetes Care. 2013;36(3):522-28.

Jarvinen HY. An investigational new insulin U300: glucose control and hypoglycaemia in people with type 2 diabetes on basal insulin and OADs. 2013:2-6.

Vaughn DE, Yocum RC, Muchmore DB, Sugarman BJ, Vick AM, Bilinsky IP et al. Accelerated pharmacokinetics and glucodynamicsoof prandial insulins injected with recombinant human hyaluronidase. Diabetes Technol Ther. 2009;11(6):345-52.

Levin P, Wei W, Wang L, Pan C, Douglas D, Baser O. Combination therapy with insulin glargine and exenatide: real-world outcomes in patients with type 2 diabetes. Curr Med Res Opin. 2012;28(3):439-46.

Levin PA, Mersey JH, Zhou S, Bromberger LA. Clinical outcomes using long-term combination therapy with insulin glargine and exenatide in patients with type 2 diabetes mellitus. Endocr Pract. 2012;18(1):17-25.

Riddle MC, Aronson R, Home P, Marre M, Niemoeller E, Miossec P, et al. Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin: a 24-week, randomized, placebo-controlled comparison (GetGoal-L). Diabetes Care. 2013;36(9):2489-96.

Riddle MC, Forst T, Aronson R, Reyna LS, Souhami E, Silvestre L, et al. Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine: a 24-week, randomized placebo-controlled study (GetGoal-Duo 1). Diabetes Care. 2013;36(9):2497-2503.

Gough SCL, Bode B, Woo V, Rodbard HW, Linjawi S, Poulsen P et al. Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide compared to each of its components given alone: results of a phase 3, randomised, 26-week, treat to-target trial in insulin-naïve patients with type 2 diabetes. Lancet Diabetes Endocrinol. 2014;2(11):885-93.

Efficacy and safety of insulin glargine/gixisenatide fixed combination versus insulin glargine alone on top of metformin in type 2 diabetic patients. Available at: http://clinicaltrials.gov/ct2/ show/NCT01476475.

Petznick A. Insulin Management of Type 2 Diabetes Mellitus. 2011;84(2):183-90.